---
layout: post
title: "Expedited Program for Serious Conditions-Accelerated Approval of Drugs and Biologics; Draft Guidance for Industry; Extension of Comment Period"
date: 2026-02-04 21:49:42 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-01179
original_published: 2025-01-17 00:00:00 +0000
significance: 8.00
---

# Expedited Program for Serious Conditions-Accelerated Approval of Drugs and Biologics; Draft Guidance for Industry; Extension of Comment Period

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** January 17, 2025 00:00 UTC
**Document Number:** 2025-01179

## Summary

The Food and Drug Administration (FDA or the Agency) is extending the comment period for the draft guidance for industry entitled "Expedited Program for Serious Conditions--Accelerated Approval of Drugs and Biologics" that appeared in the Federal Register of December 6, 2024. In the notice of availability for the draft guidance, FDA requested comments on the draft guidance. The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/01/17/2025-01179/expedited-program-for-serious-conditions-accelerated-approval-of-drugs-and-biologics-draft-guidance)
- API: https://www.federalregister.gov/api/v1/documents/2025-01179

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
